It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia. While the accumulation of Aβ is pivotal to the etiology of AD, both the microtubule-associated protein tau (MAPT) and the F-actin severing protein cofilin are necessary for the deleterious effects of Aβ. However, the molecular link between tau and cofilin remains unclear. In this study, we found that cofilin competes with tau for direct microtubule binding in vitro, in cells, and in vivo, which inhibits tau-induced microtubule assembly. Genetic reduction of cofilin mitigates tauopathy and synaptic defects in Tau-P301S mice and movement deficits in tau transgenic C. elegans. The pathogenic effects of cofilin are selectively mediated by activated cofilin, as active but not inactive cofilin selectively interacts with tubulin, destabilizes microtubules, and promotes tauopathy. These results therefore indicate that activated cofilin plays an essential intermediary role in neurotoxic signaling that promotes tauopathy.
Jung-A A. Woo et al. show that activated cofilin competes with Tau for microtubule biding in primary neuronal cultures and a C.elegans model. This direct binding decreases microtubule stability and promotes tauopathy, suggesting an important role for cofilin in neurotoxic signaling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Morsani College of Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); Morsani College of Medicine, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
2 Morsani College of Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); Morsani College of Medicine, Department of Molecular Medicine, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
3 Morsani College of Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
4 Morsani College of Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); Morsani College of Medicine, Department of Molecular Medicine, University of South Florida, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); James A. Haley Veteran’s Administration Hospital, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286)